

Collaborative Working Project Executive Summary

Improving Lung Cancer early detection rates, ensure equitable access to lung health checks and reduce health inequalities.

Project Title

A collaborative Working Agreement between NHS Southwest London ICB and Johnson and Johnson Innovative Medicines, to address disparities in lung cancer diagnosis and treatment outcomes by leveraging artificial intelligence (AI) tools and local data insights.

Partner Organisations

NHS Southwest London ICB, 120 The Broadway, Greater, London SW19 1RH

Johnson and Johnson, 50-100 Holmers Farm Way, High Wycombe HP12 4EG.

Project Rational

Lung cancer is a leading cause of cancer mortality in the UK, with approximately 48,000 new cases and 35,000 deaths annually. Early detection significantly improves outcomes, yet disparities in access and timely diagnosis persist, especially among socioeconomically disadvantaged and minority ethnic groups.

The trust has identified that the creation of a robust AI lung cancer predictive tool tailored to Southwest London, but capable of scalability, with the aim of improving early lung cancer detection may benefit Southwest London' populations, both within the targeted lung health check population and those falling outside the inclusion criteria.

Project Period: December 2025 – August 2026.

Project Objectives

Patient Specific:

Reduction in time for patients to access appropriate treatments. Reduction in delay for patients for follow-up and review of their treatment thereby having a potential to reduce complications associated with their treatment. Improvement in patient experience by ensuring a quicker more streamlined process to treatment decisions.

NHS Specific:

Increase the number of appropriate referrals through the National Optimal Lung Cancer Pathway (NOLCP) from Primary Care. Facilitating faster access to specialist services for appropriate patients. Reduction in health inequalities.

Johnson and Johnson company specific:

Greater understanding of the needs of the patients in Lung Cancer. Potential appropriate use of J&J medicines. Remove inequalities and tackle the challenges of access to services, improving health outcomes and health inequalities.

Contact Details

Johnson and Johnson company: Maria Walsh, Business Unit Director.

NHS Southwest London ICB, Martin Ellis, Chief Digital Information Officer.

November|2025 CP:551291